Stock Events

Stock Events

Galapagos NV 

M$665.65
214
+M$0+0% Tuesday 16:06

Statistics

Day High
665.65
Day Low
665.65
52W High
728.05
52W Low
647.25
Volume
0
Avg. Volume
407
Mkt Cap
43.86B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24FebExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-66.97
-42.6
-18.23
6.14
Expected EPS
-3.605304622635384
Actual EPS
N/A

Financials

21.61%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
13.09BRevenue
2.83BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLPGN.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where both companies are developing treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences collaborates with Galapagos on filgotinib but also competes in other areas of biopharmaceuticals, including antiviral drugs.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the immunology space, particularly in treatments for rheumatoid arthritis, where Galapagos also has interests.
AMGEN
AMGN
Mkt Cap160.66B
Amgen competes in the biotech space, focusing on innovative therapeutics, including areas like inflammation where Galapagos is active.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in developing treatments for conditions like asthma and arthritis, directly competing with Galapagos' pipeline.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes in the area of biopharmaceuticals with a focus on neurodegenerative diseases, an area Galapagos has shown interest in.
Novartis
NVS
Mkt Cap237.61B
Novartis competes across a broad range of therapeutic areas, including those targeted by Galapagos, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer operates in various therapeutic areas, including inflammation and immunology, competing with Galapagos' research and development efforts.
Merck
MRK
Mkt Cap214.76B
Merck & Co. competes in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Galapagos' interests.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes in multiple areas, including respiratory diseases, where Galapagos also focuses its research efforts.

About

There is no Profile data available for GLPG.BR.
Show more...
CEO
ISIN
BE0003818359

Listings

MX
MX
GLPGN.MX
XETRA
DE
GXE.XETRA
BR
BE
GLPG.BR
F
DE
GXEA.F

0 Comments

Share your thoughts

FAQ

What is Galapagos NV stock price today?▼
The current price of GLPGN.MX is M$665.65 MXN — it has increased by +0% in the past 24 hours. Watch Galapagos NV stock price performance more closely on the chart.
What is Galapagos NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galapagos NV stocks are traded under the ticker GLPGN.MX.
What is Galapagos NV market cap?▼
Today Galapagos NV has the market capitalization of 43.86B
When is the next Galapagos NV earnings date?▼
Galapagos NV is going to release the next earnings report on February 24, 2026.
What were Galapagos NV earnings last quarter?▼
GLPGN.MX earnings for the last quarter are -66.97 MXN per share, whereas the estimation was -8.94 MXN resulting in a -648.78% surprise. The estimated earnings for the next quarter are N/A MXN per share.
What is Galapagos NV revenue for the last year?▼
Galapagos NV revenue for the last year amounts to 13.09B MXN.
What is Galapagos NV net income for the last year?▼
GLPGN.MX net income for the last year is 2.83B MXN.
When did Galapagos NV complete a stock split?▼
Galapagos NV has not had any recent stock splits.